Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Prostatic Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Uterine Cervical Neoplasms

Adenocarcinoma, Clear Cell

Adenomyoepithelioma

Endometrial Neoplasms

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Endocrine System Diseases

Gonadal Disorders

Uterine Neoplasms

Uterine Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Fallopian Tube Cancer

Epithelial-myoepithelial Carcinoma

All Drugs and Chemicals

Antibodies

Antibodies, Bispecific

Immunoglobulins

vudalimab

Patti McGovern

Ginger Lee

Jolene Shore, MD

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab in patients with selected advanced gynecologic and genitourinary malignancies and to identify tumor types for further evaluation.

In Stage 1, subjects will be enrolled into 1 of 5 tumor-specific, parallel cohorts (n = 10 each):

* Platinum-resistant high-grade serous ovarian cancer (HGSOC)
* Chemotherapy relapsed or refractory clear cell ovarian, endometrial, or peritoneal cancer
* Immune-checkpoint-inhibitor-refractory microsatellite stable (MSS) endometrial cancer (EC)
* Previously treated recurrent or metastatic cervical cancer
* High-risk metastatic castration-resistant prostate cancer (mCRPC)

Within each tumor-specific cohort in Stage 1, a primary endpoint of ORR at 12 weeks, based on investigator review, will be used to determine cohort expansion into Stage 2. Each Stage 1 cohort that achieves an ORR of ≥ 20% (at least 2 out of 10 subjects with an objective response) will enroll up to an additional 20 subjects in Stage 2. Cohorts with an ORR of less than 20% will discontinue enrollment. However, additional factors will be considered in determining an expansion into Stage 2 (eg, enrollment rate, complete versus partial response, and DOR).

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer

To determine the Objective Response Rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

ICON plc

Xencor, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies	NCT05032040	Ovarian Cancer Clear Cell Carc... Endometrial Can... Cervical Carcin... Metastatic Cast...	vudalimab	18 Years -	Xencor, Inc.
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies	NCT05032040	Ovarian Cancer Clear Cell Carc... Endometrial Can... Cervical Carcin... Metastatic Cast...	vudalimab	18 Years -	Xencor, Inc.

Spots Global Cancer Trial Database for gynecological cancer,